Raptor Announces Phase 2b Trial of RP103 for NAFLD in Children Meets Enrollment Target

by Charles Gross, Benzinga Editor
January 13, 2014 7:04 AM | 15 seconds read |
Raptor Pharmaceutical RPTP today announced that its Phase 2b clinical trial, to evaluate the safety and potential efficacy of RP103 delayed-release cysteamine bitartrate as a prospective treatment of non-alcoholic fatty liver disease (NAFLD) in children, has met its enrollment target. See full press release
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsGuidanceContractsManagementGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!